AU2019335014A1 - Allogeneic cell compositions and methods of use - Google Patents

Allogeneic cell compositions and methods of use Download PDF

Info

Publication number
AU2019335014A1
AU2019335014A1 AU2019335014A AU2019335014A AU2019335014A1 AU 2019335014 A1 AU2019335014 A1 AU 2019335014A1 AU 2019335014 A AU2019335014 A AU 2019335014A AU 2019335014 A AU2019335014 A AU 2019335014A AU 2019335014 A1 AU2019335014 A1 AU 2019335014A1
Authority
AU
Australia
Prior art keywords
cell
cells
modified
csr
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2019335014A
Other languages
English (en)
Inventor
Eric M. Ostertag
Devon SHEDLOCK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poseida Therapeutics Inc
Original Assignee
Poseida Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poseida Therapeutics Inc filed Critical Poseida Therapeutics Inc
Publication of AU2019335014A1 publication Critical patent/AU2019335014A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70507—CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
AU2019335014A 2018-09-05 2019-09-05 Allogeneic cell compositions and methods of use Pending AU2019335014A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862727498P 2018-09-05 2018-09-05
US62/727,498 2018-09-05
US201862744073P 2018-10-10 2018-10-10
US62/744,073 2018-10-10
US201962815334P 2019-03-07 2019-03-07
US62/815,334 2019-03-07
US201962815880P 2019-03-08 2019-03-08
US62/815,880 2019-03-08
PCT/US2019/049816 WO2020051374A1 (en) 2018-09-05 2019-09-05 Allogeneic cell compositions and methods of use

Publications (1)

Publication Number Publication Date
AU2019335014A1 true AU2019335014A1 (en) 2021-03-25

Family

ID=68136519

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019335014A Pending AU2019335014A1 (en) 2018-09-05 2019-09-05 Allogeneic cell compositions and methods of use

Country Status (8)

Country Link
US (1) US20220389077A1 (enExample)
EP (1) EP3847197A1 (enExample)
JP (2) JP7605735B2 (enExample)
KR (1) KR20210073520A (enExample)
CN (2) CN119119296A (enExample)
AU (1) AU2019335014A1 (enExample)
CA (1) CA3111384A1 (enExample)
WO (1) WO2020051374A1 (enExample)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018329741B2 (en) 2017-09-08 2025-02-20 Poseida Therapeutics, Inc. Compositions and methods for chimeric ligand receptor (CLR)-mediated conditional gene expression
EP3773626A4 (en) * 2018-03-28 2022-01-05 Board of Regents, The University of Texas System USING HISTONE MODIFIERS TO REPROGRAM LYMPHOCYTES AND EFFECTORS
SG10201802979VA (en) * 2018-04-10 2019-11-28 Kah Meng Lim Immunological extract and method of production
WO2020117715A1 (en) 2018-12-03 2020-06-11 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment
AU2020261411B2 (en) 2019-04-26 2025-10-02 Allogene Therapeutics, Inc. Methods of manufacturing allogeneic car T cells
CN114761424B (zh) * 2019-09-05 2025-09-19 波赛达治疗公司 同种异体细胞组合物和使用方法
WO2021146487A2 (en) * 2020-01-14 2021-07-22 Synthekine, Inc. Il2 orthologs and methods of use
WO2021183795A1 (en) * 2020-03-11 2021-09-16 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
KR20210121585A (ko) * 2020-03-30 2021-10-08 한국세라믹기술원 반응성 및 안정성 그리고 항체회수가 향상된 z-도메인 및 칼시퀘스트린 융합단백질 및 이를 이용한 항체의 분리 및 정제 방법
US20230293687A1 (en) * 2020-07-29 2023-09-21 Eureka Therapeutics, Inc. T cells and chimeric stimulating receptors and uses thereof
CN112375138B (zh) * 2020-11-13 2022-12-13 中元汇吉生物技术股份有限公司 一种重组载脂蛋白e和应用
CN112402592B (zh) * 2020-12-04 2023-06-02 中国人民解放军陆军军医大学 Spink7蛋白在制备促进过度炎症创面愈合的药物中的应用
CN112480242B (zh) * 2020-12-04 2023-06-06 中国人民解放军陆军军医大学 Spink7蛋白在制备预防和/或治疗溃疡性结肠炎的药物中的应用
JP2024500870A (ja) * 2020-12-18 2024-01-10 カリナン アンバー コーポレイション 二官能性線状融合コラーゲン局在化免疫調節分子およびその方法
CN112941039A (zh) * 2021-02-01 2021-06-11 南京大学 一种新型类囊泡溶瘤病毒及其在制备抗肿瘤药物上的应用
WO2022192895A1 (en) * 2021-03-10 2022-09-15 H. Lee Moffitt Cancer Center And Research Institute Inc. Compositions and methods to reduce therapeutic t cell toxicity
CN113249361A (zh) * 2021-03-29 2021-08-13 南京欧凯生物科技有限公司 基质金属蛋白酶及其制备方法
CN117529333A (zh) 2021-04-16 2024-02-06 细胞基因公司 对先前进行过干细胞移植的患者的t细胞疗法
EP4082560B1 (en) * 2021-04-27 2025-02-26 Academia Sinica Prap1 polypeptide for use in treating hypertriglyceridemia
CN113481185B (zh) * 2021-08-05 2022-12-02 云南师范大学 一种耐盐β-半乳糖苷酶GalNC2-13及其制备方法和应用
CN113846070B (zh) * 2021-10-18 2023-05-16 翌圣生物科技(上海)股份有限公司 高活性的mTET2酶突变体、其编码DNA及其应用
JP2024540320A (ja) 2021-11-03 2024-10-31 セルジーン コーポレーション 骨髄腫を処置する際に使用するための、ｂ細胞成熟抗原に特異的なキメラ抗原受容体
CN113957075B (zh) * 2021-11-22 2023-04-07 百世诺(北京)医学检验实验室有限公司 突变的遗传性心律失常基因及其应用
CN116178562A (zh) * 2021-11-29 2023-05-30 四川大学华西医院 基于efna1构建的嵌合抗原受体免疫细胞制备及其应用
CN115873902A (zh) * 2021-11-30 2023-03-31 百奥赛图(北京)医药科技股份有限公司 一种cd200和/或cd200r基因人源化的非人动物及其构建方法和应用
CN114539376B (zh) * 2022-01-17 2023-06-13 中国水产科学研究院南海水产研究所 拟穴青蟹生物标记物cyp2基因及其在制备病理检测试剂中的应用
CN114487448B (zh) * 2022-01-21 2022-10-18 天津天海新域生物科技有限公司 用于检测重症肌无力相关抗体的组合物、试剂盒及应用
JP2025504002A (ja) 2022-01-28 2025-02-06 ジュノー セラピューティクス インコーポレイテッド 細胞組成物を製造する方法
CN114137231B (zh) * 2022-01-29 2022-04-29 北京大有天弘科技有限公司 一种血型不规则抗体的检测试剂盒及其应用
CN114113639B (zh) * 2022-01-29 2022-04-19 北京大有天弘科技有限公司 一种血型抗体检测方法及其应用
WO2023151620A1 (zh) * 2022-02-09 2023-08-17 恺兴生命科技(上海)有限公司 用于细胞免疫学的组合物和方法
CN114646764B (zh) * 2022-04-08 2024-11-29 华南农业大学 一种arhgap35蛋白在猪x和y精子鉴定或分离中的应用
EP4522183A2 (en) 2022-05-11 2025-03-19 Celgene Corporation Methods and uses related to t cell therapy and production of same
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
CN114958862B (zh) * 2022-05-23 2023-12-08 郑州伊美诺生物技术有限公司 检测慢性间质性肾炎的重组抗原的制备方法
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
CN114989287B (zh) * 2022-06-06 2024-04-09 孙英贤 脱乙酰化修饰的baf155蛋白及其制药用途
CN114920816B (zh) * 2022-06-06 2024-04-05 孙英贤 Baf155突变基因及其制药用途
AU2023316776A1 (en) * 2022-07-27 2025-03-13 Biocell Innovations Pte. Ltd. Production of cells and viral vectors
CN115747170B (zh) * 2022-08-29 2023-08-04 四川大学 一种豇豆褪绿斑驳病毒-多肽复合物及其在骨质疏松治疗中的应用
CN115820580A (zh) * 2022-08-31 2023-03-21 武汉爱博泰克生物科技有限公司 活性重组hTET2蛋白的表达及纯化方法
CN115558712A (zh) * 2022-09-22 2023-01-03 华中科技大学同济医学院附属协和医院 Fam177a1的新用途
CN115850512B (zh) * 2022-10-14 2025-11-07 江苏大学 一种用于靶向治疗肿瘤的重组融合蛋白及其制备方法
WO2024097905A1 (en) 2022-11-02 2024-05-10 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
CN115976004B (zh) * 2022-12-27 2024-07-09 天津科技大学 一种黄体酮17α-羟化酶突变体及其应用
KR20250162510A (ko) 2023-01-20 2025-11-18 포세이다 테라퓨틱스, 인크. 리피도이드 화합물 및 관련 조성물 및 용도
GB2626983A (en) * 2023-02-10 2024-08-14 Quell Therapeutics Ltd Protein
WO2024168192A1 (en) 2023-02-10 2024-08-15 Celgene Corporation Assessment of bcma in biological samples
CN116253778B (zh) * 2023-03-03 2025-09-23 中山大学 一种缓解长春新碱致神经病理性疼痛的多肽及其应用
CN118109416B (zh) * 2023-03-30 2024-11-22 广州百吉生物制药有限公司 功能增强型工程化免疫细胞及其制备和应用
WO2024211512A2 (en) 2023-04-05 2024-10-10 Poseida Therapeutics, Inc. Transposases and uses thereof
AU2024244453A1 (en) 2023-04-05 2025-11-13 Poseida Therapeutics, Inc. Transposase polynucleotides and uses thereof
WO2024211505A1 (en) 2023-04-05 2024-10-10 Poseida Therapeutics, Inc. Chimeric transposases and uses thereof
CN116478271B (zh) * 2023-06-19 2023-08-29 青岛大学 半滑舌鳎抗病基因PPARα及其编码蛋白的应用
CN116622712B (zh) * 2023-07-17 2024-08-30 北京艺妙神州医药科技有限公司 用于敲除t细胞中的trac和b2m的试剂和方法
CN116948015B (zh) * 2023-07-18 2024-07-05 山西锦波生物医药股份有限公司 生物合成人体结构性材料xxii型胶原蛋白的方法
WO2025029930A1 (en) * 2023-07-31 2025-02-06 Legend Biotech Ireland Limited Cells overexpressing cd31 and methods of use thereof
CN116854801A (zh) * 2023-08-21 2023-10-10 广东省人民医院 Hand1重组蛋白及其制备方法和在治疗扩张性心肌病药物中的应用
WO2025049925A2 (en) 2023-09-01 2025-03-06 Poseida Therapeutics, Inc. Lipidoid compounds and related compositions and uses
WO2025055927A1 (en) * 2023-09-13 2025-03-20 Qihan Hong Kong Limited Immunotherapies using hypoimmunogenic engineered cells
WO2025064507A1 (en) 2023-09-19 2025-03-27 Poseida Therapeutics, Inc. Compositions and methods for integration of viral vectors
CN117586418B (zh) * 2023-11-08 2025-07-15 东南大学 一种丝氨酸蛋白酶抑制剂及其应用
WO2025106376A1 (en) * 2023-11-17 2025-05-22 Dna Twopointo Inc. Mammalian cell lines for transient protein production
CN117551621B (zh) * 2023-11-20 2024-04-30 梅州市人民医院(梅州市医学科学院) 一种杂交瘤细胞株l008、单克隆抗体及其应用
CN117883382B (zh) * 2023-11-27 2025-02-14 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 高效递送疫苗的脂质体载体及脂质体疫苗的制备与用途
CN117820434B (zh) * 2023-12-31 2024-11-19 武汉优恩生物科技有限公司 牛羊妊娠相关糖蛋白的多肽抗原及应用
WO2025156492A1 (zh) * 2024-01-23 2025-07-31 星尘股份有限公司 转座酶及其用途
WO2025160432A1 (en) 2024-01-26 2025-07-31 Poseida Therapeutics, Inc. Methods and compositions for enhancing in vivo persistence and potency of cell therapy
CN117919389B (zh) * 2024-03-22 2024-07-23 上海南方模式生物科技股份有限公司 肿瘤新抗原dna疫苗
WO2025221789A1 (en) 2024-04-16 2025-10-23 Poseida Therapeutics, Inc. Compositions and methods for use in car/tcr cell therapies
CN118308420B (zh) * 2024-04-19 2025-06-03 东北农业大学 一种大豆基因Glyma.18G041900的应用
CN118360271B (zh) * 2024-05-07 2025-12-05 中国海洋大学 一种脂肪酶突变体及其在提升白酒酯类风味物质中的应用
CN118240829B (zh) * 2024-05-21 2024-07-23 华南农业大学 NompC基因在防治桔小实蝇中的应用
CN119736407A (zh) * 2024-12-27 2025-04-01 西北农林科技大学 一种提高动物生长速度和大小的stc2基因编码序列突变体的应用
CN119899820A (zh) * 2025-01-23 2025-04-29 深圳开悦生命科技有限公司 Dhx8融合蛋白及其制备方法
CN120209114A (zh) * 2025-03-07 2025-06-27 首都医科大学 一种含有penk蛋白的组合物及其应用
CN119874865B (zh) * 2025-03-11 2025-11-25 东北林业大学 一种溪荪ost48蛋白在植物促分蘖中的应用
CN120192430B (zh) * 2025-03-24 2025-08-22 安康市中心医院 一种基于硒修饰的心肌保护多肽及其制备方法与应用
CN119978086B (zh) * 2025-03-31 2025-10-17 中国农业大学 一种调控植物生长发育的蛋白质dap1及其编码基因和应用
CN120607598A (zh) * 2025-05-16 2025-09-09 安徽大学 人源先锋转录因子sox15 hmg结构域重组蛋白及其制备方法
CN120591344A (zh) * 2025-06-13 2025-09-05 广州景旸生物科技有限公司 Col3a1蛋白的制备方法及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4766067A (en) 1985-05-31 1988-08-23 President And Fellows Of Harvard College Gene amplification
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US4921794A (en) 1987-01-14 1990-05-01 President And Fellows Of Harvard College T7 DNA polymerase
US4795699A (en) 1987-01-14 1989-01-03 President And Fellows Of Harvard College T7 DNA polymerase
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5066584A (en) 1988-09-23 1991-11-19 Cetus Corporation Methods for generating single stranded dna by the polymerase chain reaction
US5091310A (en) 1988-09-23 1992-02-25 Cetus Corporation Structure-independent dna amplification by the polymerase chain reaction
US5142033A (en) 1988-09-23 1992-08-25 Hoffmann-La Roche Inc. Structure-independent DNA amplification by the polymerase chain reaction
US4994370A (en) 1989-01-03 1991-02-19 The United States Of America As Represented By The Department Of Health And Human Services DNA amplification technique
US5266491A (en) 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
US5580734A (en) 1990-07-13 1996-12-03 Transkaryotic Therapies, Inc. Method of producing a physical map contigous DNA sequences
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5712149A (en) * 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
ES2828982T3 (es) * 2013-05-14 2021-05-28 Univ Texas Aplicación humana de células t de receptor de antígeno quimérico (car) diseñadas
JP7054622B2 (ja) * 2014-07-21 2022-04-14 ノバルティス アーゲー ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置
GB201415347D0 (en) * 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
CA2959168A1 (en) * 2014-09-02 2016-03-10 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides
IL310729A (en) * 2016-04-15 2024-04-01 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
JP7114490B2 (ja) * 2016-06-24 2022-08-08 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
AU2018236461B2 (en) * 2017-03-17 2025-03-27 Fred Hutchinson Cancer Center Immunomodulatory fusion proteins and uses thereof
EP3665271A4 (en) * 2017-08-08 2021-04-28 Sangamo Therapeutics, Inc. CELL TARGETING MEDIA BY A CHEMICAL ANTIGEN RECEPTOR
AU2019230192A1 (en) * 2018-03-07 2020-10-08 Poseida Therapeutics, Inc. CARTyrin compositions and methods for use

Also Published As

Publication number Publication date
US20220389077A1 (en) 2022-12-08
JP2025028160A (ja) 2025-02-28
JP7605735B2 (ja) 2024-12-24
CN113383018B (zh) 2024-09-10
EP3847197A1 (en) 2021-07-14
CA3111384A1 (en) 2020-03-12
CN119119296A (zh) 2024-12-13
CN113383018A (zh) 2021-09-10
WO2020051374A1 (en) 2020-03-12
JP2021536249A (ja) 2021-12-27
WO2020051374A9 (en) 2021-07-15
KR20210073520A (ko) 2021-06-21

Similar Documents

Publication Publication Date Title
AU2019335014A1 (en) Allogeneic cell compositions and methods of use
JP7749624B2 (ja) Ｖｃａｒ組成物とその利用法
US11975026B2 (en) CD19 and CD22 chimeric antigen receptors and uses thereof
JP7399866B2 (ja) ＣＡＲＴｙｒｉｎ組成物とその利用方法
WO2019051424A9 (en) Compositions and methods for chimeric ligand receptor (clr)-mediated conditional gene expression
KR102542533B1 (ko) 표적화 핵산 나노수송체를 이용하여 치료 세포를 프로그램화하기 위한 조성물 및 방법
US12037407B2 (en) Immune cells having co-expressed shRNAS and logic gate systems
KR20170029009A (ko) Cd33 키메라 항원 수용체를 사용한 암의 치료
US20220235380A1 (en) Immune cells having co-expressed shrnas and logic gate systems
US20250082682A1 (en) Systems of engineered receptors targeting psma and ca9
RU2847299C1 (ru) Химерные антигенные рецепторы для cd19 и cd22 и пути их применения
RU2792187C2 (ru) Композиции cart-иринов и способы их применения
TW202307210A (zh) Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途